Single Cell Multiomics Market By Type (Single Cell Genomics, Single Cell Proteomics, Single Cell Transcriptomics, Single Cell Metabolomics), Technique (Single Cell Isolation & Dispensing, Single Cell Analysis), Application (Oncology, Cell Biology, Neurology, Immunology, Stem Cell Research), End-User (Academic Institutes, Contract Research Organizations, Pharmaceutical & Biotech Companies), & Regio

Single Cell Multi-Omics Market Valuation – 2024-2031

The single-cell sequencing technologies that have significantly improved the sensitivity and accuracy of analyzing individual cells across various omics levels are the main drivers of the single-cell multiomics market. These technologies have also fueled the adoption of these technologies for precision medicine applications as the need for personalized healthcare solutions grows. According to the analyst from Market Research, the single-cell multiomics market is estimated to reach a valuation of USD 9.09 Billion over the forecast subjugating around USD 3.11 Billion valued in 2024.

The growing demand for personalized medicine, as well as the growing emphasis on understanding cellular heterogeneity and its role in disease progression, are also driving the growth of the single-cell multiomics market, as these technologies provide unprecedented insights into individual cells’ complex molecular profiles, allowing researchers and clinicians to develop more targeted and effective therapies. It enables the market to grow at a CAGR of 15.82% from 2024 to 2031.

Single Cell Multiomics MarketDefinition/ Overview

Single Cell Multiomics is the simultaneous measurement and study of many molecular properties (including DNA, RNA, proteins, and epigenetics) within individual cells. This powerful approach delivers unparalleled insights into cellular heterogeneity and allows for a more thorough knowledge of complex biological systems than standard bulk analyses, which average information across huge cell populations.

How Does Increasing Prevalence of Cancer Drives the Growth of the Market?

Cancer is becoming more common, necessitating the development of improved diagnosis and therapy technologies such as single-cell multiomics. According to the World Health Organization (WHO), cancer killed about 10 million people in 2020, accounting for approximately one in every six deaths. According to the Global Cancer Observatory (GLOBOCAN), there were 19.3 million new cancer cases worldwide in 2020, which is expected to climb to 28.4 million by 2040. This rising cancer burden is driving research into personalized medicine techniques, which rely primarily on single-cell multiomics technology to precisely characterize tumor heterogeneity and identify targeted medicines.

Substantial funding for genomes and proteomics research is driving the single-cell multiomics market. The National Institutes of Health (NIH) in the United States has budgeted $526 million for the All of Us Research Program in fiscal year 2021, which intends to collect genetic data from one million Americans. In Europe, the Human Protein Atlas project has received about €250 million in funding since its inception. These large-scale genomics and proteomics programs are accelerating the use of single-cell multiomics technologies for full molecular characterization.

Furthermore, the rapid technological advancements in single-cell analysis and data processing are broadening the capabilities and uses of single-cell multiomics. The Human Cell Atlas project, a worldwide partnership to develop comprehensive reference maps of all human cells, has now profiled more than 25 million cells from various tissues and organs. According to the National Human Genome Research Institute, the cost of sequencing a human genome has decreased from $100 million in 2001 to $600 in 2021. This significant decrease in sequencing costs, combined with advances in single-cell isolation and analysis techniques, is making single-cell multiomics more accessible and boosting market growth.

What are the Primary Challenges Impacting the Single Cell Multiomics Market?

The single-cell multiomics field has technological obstacles such as scalability, repeatability, and data integration. Limitations in single-cell isolation, sequencing accuracy, and computer capacity impede mainstream acceptance and clinical application of these technologies.

Furthermore, Patents, license agreements, and intellectual property rights for single-cell multiomics technologies impede commercialization, innovation, and collaboration. Patent conflicts, private limitations, and competitive pressures stymie the development of open-access materials and established protocols, limiting access to important technology and impeding effective knowledge sharing.

Category-Wise Acumens

What are the Factors Supporting the Dominance of Single Cell Genomics?

According to analysis, the single-cell genomics segment is estimated to hold the largest market share during the forecast period. The fast development of improved single-cell sequencing techniques, such as single-cell whole-genome sequencing, single-cell whole-exome sequencing, and single-cell whole-transcriptome sequencing, has contributed significantly to the single-cell genomics segment’s domination. These technologies provide new insights into cellular heterogeneity and gene expression profiles at the individual cell level.

The growing use of single-cell genomics in oncology, which allows for the identification of rare cell subpopulations, tracking of clonal evolution, and knowledge of drug resistance mechanisms, has been a major driver of this segment’s growth. The growing desire for individualized therapy drives the need for single-cell genetic methods.

Furthermore, the advent of full single-cell genomic profiling tools that integrate several omics layers from the same individual cells, such as DNA, RNA, and epigenetics, has transformed single-cell genomics into a powerful and versatile tool for researchers. This has strengthened the segment’s dominance in the single-cell multiomics market.

How does Oncology Propel the Growth of the Single Cell Multiomics Market?

The oncology segment is estimated to dominate the single-cell multiomics market during the forecast period. The rising incidence and frequency of many malignancies have spurred the demand for better diagnostic and therapeutic technologies. Single-cell multiomics provides unparalleled insights into tumor heterogeneity, allowing for more precise diagnosis, focused treatment selection, and disease progression tracking.

Single-cell multiomics technologies have transformed cancer research by offering a better knowledge of the molecular pathways that underpin cancer growth and progression. These findings are critical for identifying new therapeutic targets and devising individualized treatment plans.

Furthermore, the oncology field has seen a substantial shift toward customized medicine, which tailors therapies to particular patient features. Single cell multiomics plays an important part in this paradigm change by allowing the identification of specific biomarkers and the prediction of therapy responses, thereby improving patient outcomes.

Gain Access into Single Cell Multiomics Market Report Methodology

Country/Region-wise Acumens

How Does the Presence of Leading Biotechnology Companies Drive the Market in North America?

According to analyst, North America is estimated to dominate the single-cell multiomics market during the forecast period. North America is home to many of the world’s leading biotechnology businesses and research institutions, which promotes innovation in single-cell multiomics. According to the Biotechnology Innovation Organization (BIO), the United States alone has approximately 7,000 biotechnology companies, with more than 1,000 specializing in cell and gene therapies. According to the 2021 QS World University Rankings, the region is home to 46 of the world’s top 100 life science universities. This concentration of expertise and resources propels scientific progress and commercial growth in single-cell multiomics applications.

North America, particularly the United States, dominates biomedical research funding, driving the single-cell multiomics market. The National Institutes of Health (NIH) budget for fiscal year 2021 was $42.9 billion, with a significant amount going toward genomics and precision medicine efforts. Since its launch in 2012, the NIH’s Single Cell Analysis Program (SCAP) has provided funding for nearly $200 million in initiatives. This solid financing climate encourages the adoption and development of cutting-edge single-cell multiomics technologies in academic institutes and biotechnology enterprises throughout the region.

Furthermore, North America has a high burden of chronic diseases and cancer, which drives the demand for sophisticated diagnostic and research tools such as single-cell multiomics. According to the American Cancer Society, there will be around 1.9 million new cancer cases identified and 608,570 cancer deaths in the United States in 2021. According to the Centers for Disease Control and Prevention (CDC), 6 in 10 persons in the United States have at least one chronic disease, with 4 in 10 having two or more. This high disease burden is driving research and clinical uses of single-cell multiomics, which will help us understand disease mechanisms and design tailored therapeutics.

What are the Primary Factors Driving the Market in Asia Pacific?

The Asia Pacific region is estimated to exhibit the highest growth within the single-cell multiomics market during the forecast period. The Asia Pacific region is experiencing a considerable increase in cancer diagnoses, fueling demand for improved diagnostic and research tools such as single-cell multiomics. According to the World Health Organization’s International Agency for Research on Cancer (IARC), the Asia-Pacific region accounted for 49.3% of new cancer cases worldwide in 2020, with 9.5 million new cases. China alone is estimated to see 4.5 million new cancer cases every year by 2030. In response, countries such as China have established significant genomics efforts. Established in 2016, the China National GeneBank plans to sequence 1 million human genomes, 1 million plant and animal genomes, and 1 million microbial genomes, accelerating the region’s adoption of single-cell multiomics technology.

Furthermore, the Asia-Pacific region is experiencing significant expansion in biotechnology and life sciences research, which is driving the single-cell multiomics market. According to the Global Biotechnology Innovation Scorecard, Singapore, South Korea, and Japan are among the top 20 countries in biotechnology innovation. The India Brand Equity Foundation predicts that the Indian biotechnology industry will reach $150 billion by 2025, increasing at a CAGR of 16.4%. This expansion is complemented by greater financing for biomedical research. In 2019, Japan’s Cabinet Office reported that the country’s total R&D spending in life sciences surpassed ¥3.6 trillion (about $33 billion), with advanced genomics and proteomics research receiving a large amount of this funding.

Competitive Landscape

The competitive landscape of the single-cell multiomics market is marked by a dynamic and fast-changing environment, with leading competitors constantly innovating and launching breakthrough technologies to obtain a competitive advantage. The market is very competitive as businesses strive to create user-friendly platforms and end-to-end solutions that simplify experimental workflows, data analysis, and interpretation processes while catering to researchers of varying levels of competence.

Some of the prominent players operating in the single-cell multiomics market include

• Becton, Dickinson and Company
• Illumina
• Danaher Corporation
• Qiagen
• Thermo Fisher Scientific
• 10x Genomics
• Fluidigm Corporation
• NanoString Technologies
• Dolomite Bio
• Berkeley Lights

Latest Developments

• In June 2023, Illumina, a prominent producer of DNA sequencing and array-based technologies, launched the NovaSeq X and NovaSeq X Plus sequencing systems. These new systems are intended to enable high-throughput single-cell multiomics analysis, allowing researchers to investigate several molecular layers, such as DNA, RNA, and proteins, from individual cells at once.
• In April 2023, Danaher Corporation, a diversified corporation, announced the acquisition of Celsee, Inc., a provider of single-cell analytic products. Celsee’s technology enables high-throughput single-cell genomes and proteomics research, adding to Danaher’s current portfolio of single-cell analytic platforms.

Report Scope

Single Cell Multiomics Market, By Category

Type

• Single Cell Genomics
• Single Cell Proteomics
• Single Cell Transcriptomics
• Single Cell Metabolomics

Technique

• Single Cell Isolation & Dispensing
• Single Cell Analysis

Application

• Oncology
• Cell Biology
• Neurology
• Immunology
• Stem Cell Research

End-user

• Academic Institutes
• Contract Research Organizations
• Pharmaceutical & Biotech Companies

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any please connect with our sales team, who will ensure that your requirements are met.